文章摘要
何敏,刘志强,蒋玲霞,朱晓钢.进展性缺血性脑卒中经银杏蜜环口服溶液治疗基于NIHSS、NDS评分的疗效评估及对血清SAA、IL-6水平的影响[J].实用中西医结合临床,2019,19(6):
进展性缺血性脑卒中经银杏蜜环口服溶液治疗基于NIHSS、NDS评分的疗效评估及对血清SAA、IL-6水平的影响
Evaluation of the efficacy of Ginkgo biloba honeycomb oral solution for progressive ischemic stroke based on NIHSS and NDS scores and its effect on serum SAA and IL-6 levels.
投稿时间:2018-12-06  修订日期:2018-12-27
DOI:
中文关键词: 进展性缺血性脑卒中  银杏蜜环口服溶液  血清SAA水平  血清IL-6水平  疗效评估
英文关键词: progressive ischemic stroke  ginkgo honeycomb oral solution  serum SAA level  serum IL-6 level  efficacy evaluation
基金项目:
作者单位E-mail
何敏 江西省人民医院二部神经内科 南昌 330006 915374951@qq.com 
刘志强 江西省人民医院二部神经内科 南昌 330006  
蒋玲霞 江西省人民医院二部神经内科 南昌 330006  
朱晓钢* 江西省人民医院二部神经内科 南昌 330006 15079171919@163.com 
摘要点击次数: 1097
全文下载次数: 244
中文摘要:
      目的 探讨进展性缺血性脑卒中经银杏蜜环口服溶液治疗的临床疗效,并评估银杏蜜环口服液对进展性缺血性卒中患者血清SAA、IL-6水平的影响。方法 收集进展性缺血性脑卒中患者160例,随机分为治疗组、对照组,每组各80例。对照组给予急性缺血性脑卒中常规治疗,治疗组在对照组基础上加用银杏蜜环口服溶液10ml/次,3次/天口服治疗,疗程2周。对两组治疗前,治疗1周、2周后均采用NIHSS评分、NDS评分进行评估,并比较两组血清SAA、IL-6水平,评价疗效。结果 治疗1周、2周后,治疗组、对照组NIHSS评分、NDS评分均较治疗前改善,而血清SAA、IL-6水平均较治疗前下降,治疗组均优于对照组(均P<0.05)。结论 银杏蜜环口服溶液可有效改善进展性缺血性脑卒中患者神经功能缺损,促进神经功能恢复,降低血清SAA、IL-6水平,疗效显著。
英文摘要:
      ABSTRACT: Objective To investigate the clinical efficacy of Ginkgo biloba honeycomb oral solution in the treatment of progressive ischemic stroke, and to evaluate the effect of Ginkgo biloba honeycomb oral solution on serum SAA and IL-6 levels in patients with progressive ischemic stroke. Methods 160 patients with progressive ischemic stroke were randomly divided into treatment group and control group, 80 cases in each group. The control group was given routine treatment of acute ischemic stroke, and the treatment group was given Ginkgo biloba honeysuckle oral solution 10 ml / time, 3 times / day oral treatment for two weeks. NIHSS score and NDS score were used to evaluate the two groups before treatment, one week and two weeks after treatment, and serum SAA and IL-6 levels were compared between the two groups to evaluate the efficacy. Results After one week and two weeks of treatment, the NIHSS score and NDS score of the treatment group and the control group were improved, while the serum SAA and IL-6 levels were decreased. The treatment group was superior to the control group (P < 0.05). Conclusion Ginkgo biloba honeycomb oral solution can effectively improve the neurological deficit in patients with progressive ischemic stroke, promote the recovery of neurological function, and reduce the levels of serum SAA and IL-6. The curative effect is remarkable.
查看全文   查看/发表评论  下载PDF阅读器
关闭
手机扫一扫看
分享按钮